• Karin Luttropp, Johan Dalén, Axel Svedbom, Mary Dozier, Christopher M Black, and Amy Puenpatom.
• ICON Clinical Research, Plc., Stockholm, Sweden.
• Patient Prefer Adher. 2020 Jan 1; 14: 309320309-320.

PurposeTo obtain an up-to-date overview of the measurement of patient experience of switching biologic treatment in patients with inflammatory arthritis (IA) or ulcerative colitis (UC). Secondary objectives included summarizing the types of patient-reported outcomes (PROs) used (if any), and related findings; and summarizing medical and non-medical reasons for treatment switch and/or discontinuation.MethodsA systematic literature review (SLR) was performed, searching Medline and Embase for relevant publications.ResultsIn total, 70 relevant publications were identified. While the majority of these reported reasons for switching and/or discontinuing treatment, only four provided information explicitly regarding patient-reported experience of switching biologic treatment. All four utilized ranking tools to assess patient experience of switching biologic treatment. The most common reason for switching and/or discontinuing treatment was loss of efficacy, while the least common reason was patient preference.ConclusionAlthough the number of available treatments in IA and UC have increased, there is a sparsity of information regarding patient-reported experience of switching biologic treatment. Further research regarding patient preference and/or experience would benefit this therapeutic area and help guide treatment choices.© 2020 Luttropp et al.

6 keywords...

hide…